A human nasal fluid complement factor antimicrobial peptide C4-AⅡ and its application
By using human nasal fluid complement factor antimicrobial peptide C4-AⅡ to disrupt the cell membrane of Staphylococcus aureus and inhibit DNA synthesis, this method solves the problems of antibiotic resistance and the impact of food sterilization methods on nutritional value in existing technologies, achieving a safe and efficient antibacterial effect.
Patent Information
- Application Number
- CN202310488951.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-04
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-05-04
AI Technical Summary
Existing technologies for treating Staphylococcus aureus infections suffer from problems such as antibiotic resistance and the impact of high-temperature and high-pressure sterilization on the sensory and nutritional value of food. There is a lack of safe and drug-free antibacterial methods.
We provide human nasal fluid complement factor antimicrobial peptide C4-AⅡ, with the amino acid sequence RHLVPGAPFLLQALVR. It inhibits bacterial growth by disrupting bacterial cell membranes and binding to bacterial DNA, and can be used to prepare antimicrobial drugs, food preservatives, and feed additives.
It effectively inhibits Staphylococcus aureus, maintains food safety and nutritional value, and poses no risk of drug resistance.
Smart Images

Figure CN116640186B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biotechnology, and in particular to a human nasal fluid complement factor antimicrobial peptide C4-AⅡ and its applications. Background Technology
[0002] Staphylococcus aureus ( Staphylococcus aureus Staphylococcus aureus (SAA) is a clinically important Gram-positive pathogen that can colonize the skin and mucous membranes of humans and animals, thus evading the immune system and causing multiple infections in different tissues, such as endocarditis, sepsis, and necrotizing pneumonia. SAA is also one of the pathogens causing foodborne illnesses, spreading through meat, dairy products, or seafood, leading to food poisoning. Currently, the main sterilization methods for SAA infection are antibiotics, ultraviolet irradiation, and high-temperature, high-pressure treatment. However, these methods have limitations; for example, antibiotic treatment can easily lead to microbial resistance, and ultraviolet and high-temperature, high-pressure sterilization techniques can affect the sensory and nutritional value of food. Therefore, finding a novel method with significant antibacterial effect and without drug resistance is urgently needed. Antimicrobial peptides (AMPs) are a class of small peptides widely found in organisms in nature and are an important component of the body's innate immune system. They are characterized by good water solubility, low toxicity to higher animals, and no drug resistance, and are considered a potential alternative to antibiotics, showing promising application prospects in the pharmaceutical industry and food additives.
[0003] Therefore, providing an antimicrobial peptide that can effectively inhibit Staphylococcus aureus infection while maintaining good stability is a technical problem that urgently needs to be solved in this field. Summary of the Invention The purpose of this invention is to overcome the shortcomings of the prior art and provide a human nasal fluid complement factor antimicrobial peptide C4-AⅡ and its application, thereby solving the problems in the background art.
[0004] One of the technical solutions adopted by this invention to solve its technical problem is to provide a human nasal fluid complement factor antimicrobial peptide C4-AⅡ. Its amino acid sequence is RHLVPGAPFLLQALVR, as shown in SEQ ID NO: 1.
[0005] First, mass spectrometry analysis of human nasal fluid yielded and identified 1859 peptide sequences. Then, using the Swiss-model server, peptide structures were predicted, revealing an antimicrobial peptide sequence RHLVPGAPFLLQALVR with strong antibacterial activity against Staphylococcus aureus, which was named C4-AⅡ.
[0006] The antimicrobial peptide C4-AII has a molecular weight of 1787.19 Daltons, a charge of +2.25, and a total hydrophobicity of 56%.
[0007] Antimicrobial peptide C4-AI can damage bacteria in the following ways: First, the positive charge of antimicrobial peptide C4-AI can interact with the bacterial cell membrane, adsorb onto the surface of the bacterial cell membrane, and damage the cell membrane, leading to bacterial death. Second, while damaging the cell membrane, it also changes the permeability of the bacterial cell membrane and inhibits cell membrane formation, leading to bacterial death. Third, it can bind to bacterial genomic DNA, inhibiting bacterial DNA synthesis, thereby leading to bacterial death.
[0008] The second technical solution adopted by the present invention to solve its technical problem is: to provide the application of human nasal fluid complement factor antimicrobial peptide C4-AⅡ in the preparation of antimicrobial drugs, which are used to inhibit and / or kill Staphylococcus aureus.
[0009] The third technical solution adopted by the present invention to solve its technical problem is: to provide an antibacterial drug, the effective component of which includes human nasal fluid complement factor antimicrobial peptide C4-AⅡ, wherein the amino acid sequence of the antimicrobial peptide C4-AⅡ is SEQ ID NO: 1.
[0010] In a preferred embodiment of the present invention, the active ingredient of the antibacterial drug is the nasal fluid complement factor antimicrobial peptide C4-AⅡ, and the amino acid sequence of the antimicrobial peptide C4-AⅡ is SEQ ID NO: 1.
[0011] In a preferred embodiment of the present invention, the antibacterial drug is used to inhibit and / or kill Staphylococcus aureus.
[0012] The fourth technical solution adopted by the present invention to solve its technical problem is: to provide a food preservative, the effective component of which is human nasal fluid complement factor antimicrobial peptide C4-AⅡ, the amino acid sequence of which is SEQ ID NO: 1.
[0013] In a preferred embodiment of the present invention, the food preservative is used to inhibit and / or kill Staphylococcus aureus.
[0014] The fifth technical solution adopted by the present invention to solve its technical problem is: to provide a feed additive whose effective ingredient includes human nasal fluid complement factor antimicrobial peptide C4-AⅡ, wherein the amino acid sequence of the antimicrobial peptide C4-AⅡ is SEQ ID NO: 1.
[0015] In a preferred embodiment of the present invention, the active ingredient of the feed additive is human nasal fluid complement factor antimicrobial peptide C4-AⅡ, and the amino acid sequence of the antimicrobial peptide C4-AⅡ is SEQ ID NO: 1.
[0016] In a preferred embodiment of the present invention, the feed additive is used to inhibit and / or kill Staphylococcus aureus.
[0017] The antimicrobial peptides of the present invention can be synthesized using methods known to those skilled in the art, such as solid-phase synthesis, and purified using methods known to those skilled in the art, such as high-performance liquid chromatography.
[0018] Implementing this invention has the following beneficial effects: This invention uses human nasal secretions as the research object. Through mass spectrometry identification and screening, a novel polypeptide C4-AⅡ with a novel amino acid sequence was discovered. The antibacterial activity of C4-AⅡ against Staphylococcus aureus was studied, and its antibacterial mechanism was investigated. The results showed that this peptide has a strong inhibitory effect on Staphylococcus aureus. Its antibacterial mechanism involves first adsorbing onto the bacterial surface, causing damage to the bacterial cell membrane, and then crossing the cell membrane to bind to the bacterial genomic DNA, inhibiting bacterial DNA synthesis, thereby leading to bacterial death. The antimicrobial peptide C4-AⅡ of this invention can be used to prepare drugs, feed additives, or food preservatives for the prevention or inhibition of Staphylococcus aureus infection. Attached Figure Description
[0019] Figure 1 This is a mass spectrometry analysis of the antimicrobial peptide C4-AⅡ.
[0020] Figure 2 This is a schematic diagram of the predicted structure of the antimicrobial peptide C4-AⅡ.
[0021] Figure 3 This is a control diagram for determining the minimum inhibitory concentration (MBC) of antimicrobial peptide C4-AⅡ against Staphylococcus aureus.
[0022] A: Antimicrobial peptide concentration 0 μg / mL; B: Antimicrobial peptide concentration 125.0 μg / mL; C: Antimicrobial peptide concentration 62.5 μg / mL; D: Antimicrobial peptide concentration 31.3 μg / mL; E: Antimicrobial peptide concentration 15.6 μg / mL; F: Antimicrobial peptide concentration 7.8 μg / mL.
[0023] Figure 4 This is a time-kill curve of the antimicrobial peptide C4-AII against Staphylococcus aureus. It was diluted to 10 μL in 0.01 M pH 7.2 phosphate buffer. 6-7 CFU / mL. The concentration of the antimicrobial peptide was 15.6 μg / mL.
[0024] Figure 5 These are images from a fluorescence microscope illustrating the observation of bacterial cell membrane permeability. A: Staphylococcus aureus blank control group; B: Staphylococcus aureus after treatment with antimicrobial peptide C4-AⅡ for 2 hours.
[0025] Figure 6 This is a diagram showing the leakage of nucleic acids and proteins after the antimicrobial peptide C4-AI acts on Staphylococcus aureus. A: Leakage of intracellular nucleic acid; B: Leakage of intracellular proteins.
[0026] Figure 7 This is a flow cytometry image of the antimicrobial peptide C4-AⅡ acting on Staphylococcus aureus.
[0027] Figure 8 This is a circular dichroism chromatogram showing the changes in secondary structure of the antimicrobial peptide C4-AⅡ when it acts on the bacterial cell membrane.
[0028] Figure 9 This is an electrophoresis image showing the binding of the antimicrobial peptide C4-AI to Staphylococcus aureus DNA. Band 6: Blank control; Bands 1-5: C4-AII to DNA mass ratios of 50 / 1, 25 / 1, 25 / 2, 25 / 4, 25 / 8, and 0, respectively.
[0029] Figure 10 This is a diagram showing the cytotoxicity of the antimicrobial peptide C4-AⅡ. Detailed Implementation
[0030] To better understand the present invention, the present invention will be further described in detail below with reference to the embodiments and accompanying drawings. However, those skilled in the art will understand that the following embodiments are not intended to limit the scope of protection of the present invention, and any changes and variations made on the basis of the present invention are within the scope of protection of the present invention.
[0031] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.
[0032] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.
[0033] Example 1: Screening of antimicrobial peptide C4-AIII First, samples were taken from human nasal fluid. After centrifugation at 1.5 mL for 15 min, the supernatant was collected and filtered through a 3000 Da filter membrane. The sample was stored at -20 °C and then further analyzed using a Nano Aquity UPLC system (Waters Corp).
[0034] Chromatographic conditions: Injection volume: 5.0 μl Chromatographic column: C18 analytical column, 25cm in length, 75μm in inner diameter. Mobile phase: A: 0.1% methanol aqueous solution B: Acetonitrile Using the search software MAXQUANT v1.6.5.0 and the database uniprot Homo sapiens (Human) protein library, the obtained peptide mass spectra were differentiated and identified, yielding 1859 peptides, such as... Figure 1 As shown in the figure. Then, the sequences were screened using two online servers, APD3 and CAMP, and the peptide structures were predicted using the Swiss-model server. An antimicrobial peptide with strong antibacterial activity against Staphylococcus aureus was discovered. The sequence is RHLVPGAPFLLQALVR, named C4-AⅡ, and the molecular weight is 1787.19 Daltons.
[0035] Example 2: 3D structure prediction of antimicrobial peptide C4-AII The structure of the antimicrobial peptide C4-AIII was predicted using the online structure prediction server Swiss-model, and then edited and modified using Pymol software to obtain the secondary structure of the antimicrobial peptide C4-AIII, such as... Figure 2 As shown.
[0036] Example 3: Determination of the minimum bactericidal concentration (MBC) of antimicrobial peptide C4-AⅡ Staphylococcus aureus was cultured at 37°C for 12 hours to reach the logarithmic growth phase, and then diluted to a final concentration of 10 μL in 0.01 M pH 7.2 phosphate buffer. 6-7 CFU / mL. Antimicrobial peptide C4-AⅡ was dissolved in phosphate buffer and incubated with an equal volume of Staphylococcus aureus at 37°C for 2 hours. The minimum bactericidal concentration (MBC) is the lowest concentration of antimicrobial peptide at which no bacterial growth is observed on a microtiter plate after incubation at 37°C. For example... Figure 3 As shown, the minimum bactericidal concentration (MBC) of the antimicrobial peptide C4-AⅡ against Staphylococcus aureus is 15.625 μg / mL.
[0037] Example 4: Time-kill curve determination of antimicrobial peptide C4-AⅡ The time-bacterial killing curve of the antimicrobial peptide C4-AIII was determined using the plate count method. Staphylococcus aureus was cultured at 37°C for 12 h to the logarithmic growth phase, and then diluted to 10⁻¹⁰ in 0.01 M pH 7.2 phosphate buffer. 6-7 CFU / mL. Equal volumes of 1×MBC and 2×MBC peptides were mixed with Staphylococcus aureus at 37°C and incubated separately. Samples were taken every 30 minutes and plated. After overnight incubation at 37°C, the total colony count was recorded. Figure 4 As shown, the antimicrobial peptide C4-AII exhibited a significant effect against Staphylococcus aureus starting at 0.5 hours; subsequently, the effect continued to decrease, killing Staphylococcus aureus within 3 hours. This indicates that the antimicrobial peptide C4-AII has a significant inhibitory effect on Staphylococcus aureus with increasing exposure time.
[0038] Example 5: Investigating the effect of antimicrobial peptides on cell membrane integrity using fluorescence microscopy Take 90 μL of 10 6-7 CFU suspension was added to a sterile 1.5 mL centrifuge tube, followed by 90 μL of 1×MBC antimicrobial peptide solution. Sterile water was used as a control. The tube was incubated at 37°C for 2 hours, then Propidium Iodide (PI) fluorescence staining was performed. 500 mg·L⁻¹ PI stock solution was added to bring the final PI concentration in the mixture to 50 mg·L⁻¹. The sample was incubated in the dark for 5 minutes. After washing, the sample was prepared as a slide and observed under a fluorescence microscope. Figure 5 As shown. The experiment was repeated three times. Detection and imaging were performed under a fluorescence microscope: PI detection (excitation wavelength 535 nm, emission wavelength 615 nm): filter selected was G-2A. Figure 5 As shown, no fluorescence signal was observed in Staphylococcus aureus cells not treated with antimicrobial peptide C4-AII under a single field of view; however, cells treated with antimicrobial peptide C4-AII emitted red fluorescence. These results indicate that antimicrobial peptide C4-AII affects the cell membrane integrity of Staphylococcus aureus.
[0039] Example 6: Effect of antimicrobial peptide C4-AIII on bacterial protein and nucleic acid leakage 200 μL of Staphylococcus aureus strain stored at -20℃ was inoculated into LB medium and cultured at 37℃ and 200 r / h for 12 h until the bacteria reached the logarithmic growth phase. The bacterial suspension, diluted with 0.01 M phosphate buffer, was then mixed with peptides of 1×MBC, 2×MBC, and 4×MBC concentrations in equal proportions. The OD values were measured using a multi-mode microplate reader every 10 min at intervals of 0.5 h. 260 / 280 nm was used to investigate the leakage of nucleic acids and proteins from the bacteria. An equal volume of 0.01 M phosphate buffer was mixed with bacteria in a specific ratio as a blank control. Figure 6 As shown.
[0040] Detection of absorbance at 260 nm and 280 nm can be used to estimate the amount of nucleic acids and proteins leaking from the cytoplasm. For example... Figure 6 As shown, with the increase of the concentration of antimicrobial peptide C4-AI, the amount of nucleic acid and protein in the culture medium treated with antimicrobial peptide DB16 increased in a dose-dependent manner.
[0041] Example 7: Flow Cytometry Staphylococcus aureus was cultured at 37℃ for 12 h to reach the logarithmic growth phase. 1 mL of the bacterial suspension was centrifuged in a 1.5 mL centrifuge tube at 12000 r / min for 1 min, the supernatant was removed, and the suspension was resuspended in 1 mL of sterile 0.01 M phosphate buffer. This process was repeated three times. After preparing the bacterial suspension in 0.01 M phosphate buffer, peptides at concentrations of 1×MBC and 2×MBC were mixed with the bacterial suspension in equal proportions (greater than 200 μL) and incubated at 37℃ for 2 h. 0.01 M phosphate buffer was used as a blank control. Pyridine iodide (PI) was used as the fluorescent dye. After incubation, an equal volume of 50 μg / mL PI dye was added to the mixture, and the mixture was incubated at 4℃ for 15 min before being loaded onto a flow cytometer for detection. The samples were analyzed by detecting the scattered light signal (SC) and the propidium iodide fluorescence signal (PI). Figure 7 As shown.
[0042] Example 8: Changes in the secondary structure of the bacterial cell membrane when the antimicrobial peptide C4-AIII acts on it. Antimicrobial peptide C4-AⅡ was prepared into a 0.2 mg / mL solution using 0.025 mol / L SDS and 0.01 mol / L PBS, respectively. A certain volume of the antimicrobial peptide C4-AⅡ solution was added to a quartz cuvette, and the sample was scanned in the far-ultraviolet range of 180–280 nm using a circular dichroism spectrometer at 25 °C. Data were acquired at a scan rate of 50 nm / min and a bandwidth of 1.0 nm. Noise reduction was performed on all scanned spectra using CDNN software, and the relative content of secondary structures in the sample solution was calculated by fitting the data. Figure 8 It can be seen that the changes in the secondary structure of the antimicrobial peptide C4-AI in the buffer environment and the hydrophobic environment of the simulated membrane indirectly reflect the antibacterial mechanism when the antimicrobial peptide acts on Staphylococcus aureus.
[0043] Example 9: Interaction between antimicrobial peptide C4-AI and bacterial DNA The interaction between the antimicrobial peptide C4-AIII and Staphylococcus aureus genomic DNA was investigated using the DNA gel retardation method. Staphylococcus aureus was cultured in 50 mL of nutrient broth (NB) at 37 °C for 12 h, and bacterial genomic DNA was extracted using a bacterial genomic DNA extraction kit. The optical density ratio (OD) at 260 and 280 nm was compared with that at 280 nm. 260 / OD 280 The purity of the extracted genomic DNA was evaluated using a concentration ≥1.90. 10 μl of DNA (218 ng / μL) was mixed with a continuous stream of the antimicrobial peptide C4-AⅡ at 25°C for 90 min, and the mixture was electrophoresed on a 0.8% agarose gel. Gel retardation was observed under UV irradiation using a GelDocXR gel imaging system (Bio-Rad, USA). Figure 9 As shown, after different concentrations of antimicrobial peptide C4-AI were applied to Staphylococcus aureus, no significant migration of the bacterial DNA bands occurred. This binding effect could still inhibit DNA migration even when the ratio of antimicrobial peptide C4-AI to DNA was 25 / 8.
[0044] Example 10: Cytotoxicity of antimicrobial peptide C4-AIII The cytotoxicity of antimicrobial peptide C4-AⅡ was determined using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) method. 96-well plates containing 10 mg / mL of normal human hepatocytes (LO2) were incubated at 37°C in a CO2 incubator until cell adhesion. Then, 100 µL of different concentrations of antimicrobial peptides (MBC, 2×MBC, 4×MBC, 8×MBC, and 16×MBC) were added to the 96-well plates and incubated at 37°C for 24 h. After incubation, 20 µL of MTT solution (5 mg / mL) was added, and the plates were incubated at 37°C for 4 h. The supernatant was discarded, and 150 µL of dimethyl sulfoxide was added, followed by incubation on a low-speed shaker for 10 min to dissolve and crystallize the cells. The absorbance was measured at 490 nm to determine hepatocyte viability. PBS of equal concentration was used as a blank control. Figure 10 As shown, when the concentration of antimicrobial peptide C4-AIII reaches 500 μg / mL, the cell survival rate is still above 90%.
[0045] In summary, this invention provides a novel antimicrobial peptide C4-AI with a minimum bactericidal concentration (MBC) of 15.6 μg / mL against Staphylococcus aureus, exhibiting a strong inhibitory effect on the bacteria. Its antibacterial mechanism involves first adsorbing onto the bacterial surface, causing damage to the bacterial cell membrane, then crossing the cell membrane and binding to the bacterial genomic DNA, inhibiting bacterial DNA synthesis and leading to bacterial death.
[0046] While specific embodiments of the present invention have been described above, those skilled in the art should understand that the specific embodiments described are merely illustrative and not intended to limit the scope of the present invention. Equivalent modifications and variations made by those skilled in the art in accordance with the spirit of the present invention should be covered within the scope of protection of the claims of the present invention.
Claims
1. The use of human nasal fluid complement factor antimicrobial peptide C4-AII with an amino acid sequence as shown in SEQ ID NO: 1 in the preparation of an antibacterial drug, characterized in that: The antibacterial agent is used to inhibit and / or kill Staphylococcus aureus. The antibacterial agent is used to inhibit and / or kill Staphylococcus aureus.
Citation Information
Patent Citations
Method for identifying type I diabetes mellitus in humans
US20090117578A1
